With more and more evidence linking PGC-1α and its target genes to the pathogenesis of neurodegenerative diseases including PD, HD, and mitochondrial disorders, pharmacological manipulations to restore and/or activate PGC-1α may provide valuable tools in the therapy of these currently intractable diseases. Here, PPARGC1A is linked to neurodegenerative disease.